OBJECTIVE: We evaluated the expression of epithelial cell adhesion molecule (EpCAM) and the potential of MT201 (adecatumumab), a human-monoclonal-antibody that targets EpCAM against chemotherapy-resistant ovarian disease. STUDY DESIGN: EpCAM expression was evaluated by real-time polymerase chain reaction and flow cytometry. Sensitivity to MT201 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity was tested in 4-hour chromium-release assays. The effect of interleukin-2 on MT201 ADCC was also studied. RESULTS: High messenger RNA expression by real-time polymerase chain reaction and high EpCAM surface expression by flow cytometry was detected in 71% of ovarian cancers (5 of 7 cell lines). Although these cell lines were highly resistant to complement-dependent cytotoxicity and natural killer-dependent cytotoxicity in vitro (range of killing, 0-7%), EpCAM-positive cell lines showed high sensitivity to MT201 ADCC (range of killing, 27-66%). Incubation with interleukin-2 further increased the cytotoxic activity against EpCAM-positive ovarian cancer cell lines. CONCLUSION: MT201 may represent a novel, potentially highly effective treatment option for patients with ovarian carcinoma whose body is harboring disease refractory to chemotherapy.
OBJECTIVE: We evaluated the expression of epithelial cell adhesion molecule (EpCAM) and the potential of MT201 (adecatumumab), a human-monoclonal-antibody that targets EpCAM against chemotherapy-resistant ovarian disease. STUDY DESIGN:EpCAM expression was evaluated by real-time polymerase chain reaction and flow cytometry. Sensitivity to MT201 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity was tested in 4-hour chromium-release assays. The effect of interleukin-2 on MT201 ADCC was also studied. RESULTS: High messenger RNA expression by real-time polymerase chain reaction and high EpCAM surface expression by flow cytometry was detected in 71% of ovarian cancers (5 of 7 cell lines). Although these cell lines were highly resistant to complement-dependent cytotoxicity and natural killer-dependent cytotoxicity in vitro (range of killing, 0-7%), EpCAM-positive cell lines showed high sensitivity to MT201 ADCC (range of killing, 27-66%). Incubation with interleukin-2 further increased the cytotoxic activity against EpCAM-positive ovarian cancer cell lines. CONCLUSION: MT201 may represent a novel, potentially highly effective treatment option for patients with ovarian carcinoma whose body is harboring disease refractory to chemotherapy.
Authors: Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Holger Moch; Patrick A Baeuerle; Elisabeth Mueller-Holzner; Christian Marth; Guenther Gastl; Alain G Zeimet Journal: Gynecol Oncol Date: 2006-05-06 Impact factor: 5.482
Authors: Stefania Bellone; Eric R Siegel; Emiliano Cocco; Marilisa Cargnelutti; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin Journal: Int J Gynecol Cancer Date: 2009-07 Impact factor: 3.437
Authors: Alexander Burges; Pauline Wimberger; Carolin Kümper; Vera Gorbounova; Harald Sommer; Barbara Schmalfeldt; Jacobus Pfisterer; Michail Lichinitser; Anatoliy Makhson; Vladimir Moiseyenko; Angelika Lahr; Elisabeth Schulze; Michael Jäger; Michael A Ströhlein; Markus Maria Heiss; Thomas Gottwald; Horst Lindhofer; Rainer Kimmig Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531
Authors: Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón Journal: Stem Cell Rev Rep Date: 2012-09 Impact factor: 5.739
Authors: Stefania Bellone; Jonathan Black; Diana P English; Carlton L Schwab; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin Journal: Am J Obstet Gynecol Date: 2015-08-10 Impact factor: 8.661
Authors: Emiliano Cocco; Erik M Shapiro; Sara Gasparrini; Salvatore Lopez; Carlton L Schwab; Stefania Bellone; Ileana Bortolomai; Natalia J Sumi; Elena Bonazzoli; Roberta Nicoletti; Yang Deng; W Mark Saltzman; Caroline J Zeiss; Floriana Centritto; Jonathan D Black; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Sergio Pecorelli; Alessandro D Santin Journal: Int J Cancer Date: 2015-08-18 Impact factor: 7.396
Authors: Diana P English; Stefania Bellone; Carlton L Schwab; Dana M Roque; Salvatore Lopez; Ileana Bortolomai; Emiliano Cocco; Elena Bonazzoli; Sudeshna Chatterjee; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin Journal: Cancer Date: 2014-09-23 Impact factor: 6.860
Authors: Vanessa M Peterson; Cesar M Castro; Jaehoon Chung; Nathan C Miller; Adeeti V Ullal; Maria D Castano; Richard T Penson; Hakho Lee; Michael J Birrer; Ralph Weissleder Journal: Proc Natl Acad Sci U S A Date: 2013-12-02 Impact factor: 11.205
Authors: Emiliano Cocco; Yang Deng; Erik M Shapiro; Ileana Bortolomai; Salvatore Lopez; Ken Lin; Stefania Bellone; Jiajia Cui; Gulden Menderes; Jonathan D Black; Carlton L Schwab; Elena Bonazzoli; Fan Yang; Federica Predolini; Luca Zammataro; Gary Altwerger; Christopher de Haydu; Mitchell Clark; Julio Alvarenga; Elena Ratner; Masoud Azodi; Dan-Arin Silasi; Peter E Schwartz; Babak Litkouhi; W Mark Saltzman; Alessandro D Santin Journal: Mol Cancer Ther Date: 2016-12-12 Impact factor: 6.261
Authors: B T F van der Gun; C Huisman; S Stolzenburg; H G Kazemier; M H J Ruiters; P Blancafort; M G Rots Journal: Br J Cancer Date: 2013-02-12 Impact factor: 7.640